Identification of broadly tumour-reactive γδ TCRs from multiple myeloma.
- Open access
PreGame identifies tumour-reactive γδ T-cell receptors with broad reactivity, revealing potential for universal immunotherapy in multiple myeloma and other cancers.
- Why it matters: Understanding which γδ T-cells specifically target tumours is crucial for developing effective immunotherapies, but distinguishing tumour-reactive cells from bystanders has been challenging.
- What they did: Using a machine-learning algorithm called PreGame, the study analyzed single-cell CITE sequencing data from patients with multiple myeloma and solid cancers, confirming TCR specificity to tumour cells.
- The result: Expansion of tumour-reactive γδ T-cells predicted early treatment response, and the discovery of a γδ TCR epitope in HLA-C suggests new strategies for tumour immunosurveillance and universal therapies.